ArticleEndocrine2026
Differential diagnosis of familial dysalbuminemic hyperthyroxinemia , RTH, and TSHomas: A single-center retrospective analysis.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsFamilial dysalbuminemic hyperthyroxinemia (FDH) can mimic inappropriate secretion of TSH (IST) in thyroid function tests, and conventional methods may fail to detect assay interference, potentially leading to misdiagnosis as resistance to thyroid hormone (RTH) or TSH-secreting pituitary adenoma (TSHoma).
methodsWe retrospectively analyzed hospitalized patients with suspected IST over a five-year period, identifying 12 cases each of FDH and RTH, and 37 cases of TSHoma. Characteristics of genetically confirmed FDH patients and their families were summarized. Clinical and biochemical features were compared across the three groups, with cases having confounding thyroid pathology or pituitary hormone co-secretion excluded from biochemical analyses.
resultsA positive family history was noted in 10 of 12 FDH cases, with two patients also diagnosed with papillary thyroid carcinoma and one with Graves’ disease. The FDH group showed significantly lower median TSH, FT3, and rT3 levels, along with a higher TT4 (µg/dL)/TT3 (ng/mL) ratio compared to the RTH and TSHoma groups (all p < 0.05). ROC analysis identified optimal cutoffs for distinguishing FDH: a TT4/TT3 ratio of 10.99 for FDH vs. RTH (AUC = 0.982, 90.0% sensitivity, 100.0% specificity) and 9.94 for FDH vs. TSHoma (AUC = 1.000, 100.0% sensitivity and specificity). FT3/upper limit of normal (ULN) ratio cutoffs of 1.2 (vs. RTH, AUC = 0.905) and 1.3 (vs. TSHoma, AUC = 0.872) also showed strong discriminative value (all p < 0.01). The somatostatin analogue (SSA) test showed a stepwise increase in 24-hour/2-hour TSH suppression ratio: RTH (22.83%) < FDH (40.59%) < TSHoma (75.45%) (p < 0.001).
conclusionsFDH should be carefully considered in the differential diagnosis of IST. The TT4/TT3 and FT3/ULN ratios are useful for diagnostic discrimination. The SSA test response in FDH appears physiological and may help define a diagnostic continuum between RTH and TSHoma. These findings require validation in larger cohorts.
Indexed as
Identifiers
41920220What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.